Furthermore, we observed the activation of 4-1BB signaling in CD8+ T cell after BrQ treatment, while the agonistic anti-4-1BB monoclonal antibody can suppress antigen-specific CD4+ T cells by activating CD8+ T cells in rheumatoid arthritis animal models [42]. Here, TNFRSF9 is linked to rheumatoid arthritis.